Krystal Biotech, Inc. (NASDAQ: KRYS) reported Q3 EPS of $2.66, $1.57 better than the analyst estimate of $1.09. Revenue for the quarter came in at $97.8 million versus the consensus estimate of $93.19 million.

For earnings history and earnings-related data on Krystal Biotech, Inc. (KRYS) click here.